| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/12/2023 |
8-K
| Quarterly results |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Sold 99,979 shares
@ $0.25, valued at
$25k
Sold 62,258 shares
@ $0.25, valued at
$15.6k
Sold 19,996 shares
@ $0.25, valued at
$5k
Sold 67,767 shares
@ $0.25, valued at
$16.9k
|
|
| 09/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/24/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/16/2023 |
4
| Bernard Thierry (Director) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Exercised 1,550 options to buy
@ $0
Exercised 454 options to buy
@ $0 |
|
| 08/16/2023 |
4
| Saunders Ninfa (Director) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Exercised 1,550 restricted stock units
@ $0
Exercised 454 restricted stock units
@ $0 |
|
| 08/16/2023 |
4
| Toft Robin (Director) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Exercised 454 restricted stock units
@ $0 |
|
| 08/11/2023 |
8-K
| Quarterly results, Conference call transcript |
| 08/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/31/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 07/13/2023 |
SC 13G
| CR Group L.P. reports a 19.9% stake in T2 Biosystems, Inc. |
| 07/12/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 07/12/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 07/06/2023 |
4
| CR Group L.P. (10% Owner) has filed a Form 4 on T2 Biosystems, Inc.|
Txns:
| Granted 19,334,277 shares
@ $0
Granted 12,039,660 shares
@ $0
Granted 3,866,855 shares
@ $0
Granted 13,105,006 shares
@ $0 |
|
| 07/06/2023 |
3
| CR Group L.P. (10% Owner) has filed a Form 3 on T2 Biosystems, Inc. |
| 07/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock",
"Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Purchase Agreement, by and between the Company and the Purchasers party thereto",
"Securities Purchase Agreement, by and between the Company and the Lenders party thereto",
"Consent to Term Loan Agreement, by and between the Company and CRG Servicing LLC, as administrative agent and collateral agent, and the lenders party thereto" |
|
| 06/30/2023 |
SC 13G
| GSA CAPITAL PARTNERS LLP reports a 15.2% stake in T2 Biosystems Ord |
| 06/16/2023 |
SC 13G
| Markey John reports a 17.3% stake in T2 Biosystems, Inc. |
|